Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Hynes

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Bioorganic & Medicinal Chemistry Letters|August 9, 2020
Annulation reaction enables the identification of an exocyclic amide tricyclic chemotype as retinoic acid Receptor-Related orphan receptor gamma (RORγ/RORc) inverse agonistsDavid Marcoux, Myra Beaudoin Bertrand, Carolyn A Weigelt, et al.
European Radiology|January 31, 2024
Validating the safety of low-dose CTPA in pregnancy: results from the OPTICA (Optimised CT Pulmonary Angiography in Pregnancy) StudyCiara D Gillespie, Andrew Yates, Mark Hughes, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
C-3 Amido-indole cannabinoid receptor modulatorsJohn Hynes, Katerina Leftheris, Hong Wu, et al.
Bioorganic & Medicinal Chemistry Letters|August 25, 2010
Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitorsShuqun Lin, Stephen T Wrobleski, John Hynes, et al.
Journal of Medicinal Chemistry|May 16, 2003
Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory propertiesStephen T Wrobleski, Ping Chen, John Hynes, et al.
Bioorganic & Medicinal Chemistry Letters|March 28, 2008
Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitorsStephen T Wrobleski, Shuqun Lin, John Hynes, et al.
Journal of Molecular Biology|January 13, 2015
Developing Adnectins that target SRC co-activator binding to PXR: a structural approach toward understanding promiscuity of PXRJaved A Khan, Daniel M Camac, Simon Low, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2017
Discovery of highly potent, selective, covalent inhibitors of JAK3James Kempson, Damaso Ovalle, Junqing Guo, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2008
The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitorJohn Hynes, Hong Wu, Sidney Pitt, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 23, 2016
Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing ActivityShailesh Dudhgaonkar, Sourabh Ranade, Jignesh Nagar, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry Letters|August 9, 2020
Annulation reaction enables the identification of an exocyclic amide tricyclic chemotype as retinoic acid Receptor-Related orphan receptor gamma (RORγ/RORc) inverse agonistsDavid Marcoux, Myra Beaudoin Bertrand, Carolyn A Weigelt, et al.
European Radiology|January 31, 2024
Validating the safety of low-dose CTPA in pregnancy: results from the OPTICA (Optimised CT Pulmonary Angiography in Pregnancy) StudyCiara D Gillespie, Andrew Yates, Mark Hughes, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
C-3 Amido-indole cannabinoid receptor modulatorsJohn Hynes, Katerina Leftheris, Hong Wu, et al.
Bioorganic & Medicinal Chemistry Letters|August 25, 2010
Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitorsShuqun Lin, Stephen T Wrobleski, John Hynes, et al.
Journal of Medicinal Chemistry|May 16, 2003
Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory propertiesStephen T Wrobleski, Ping Chen, John Hynes, et al.
Bioorganic & Medicinal Chemistry Letters|March 28, 2008
Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitorsStephen T Wrobleski, Shuqun Lin, John Hynes, et al.
Journal of Molecular Biology|January 13, 2015
Developing Adnectins that target SRC co-activator binding to PXR: a structural approach toward understanding promiscuity of PXRJaved A Khan, Daniel M Camac, Simon Low, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2017
Discovery of highly potent, selective, covalent inhibitors of JAK3James Kempson, Damaso Ovalle, Junqing Guo, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2008
The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitorJohn Hynes, Hong Wu, Sidney Pitt, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 23, 2016
Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing ActivityShailesh Dudhgaonkar, Sourabh Ranade, Jignesh Nagar, et al.
Pageof 6